跳至主要内容
临床试验/NCT01700140
NCT01700140已完成2 期

Phase II Clinical Study of SyB D-0701 for Radiotherapy Induced Nausea and Vomiting

SymBio Pharmaceuticals4 个研究点 分布在 1 个国家目标入组 189 人开始时间: 2011年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
189
试验地点
4
主要终点
Complete Control (no Signs of Emesis or Moderate to Severe Nausea and no Use of Rescue Medication) Rate From the Start of Radiotherapy Until 24 Hours After the Third Irradiation

研究概览

简要总结

The purpose of this study is to explore the dose response of SyB D-0701 for preventing nausea and emesis associated with radiotherapy (fractionated/localized irradiation) in cancer patients scheduled to receive radiotherapy (fractionated/localized irradiation) alone.

详细描述

Exploratory study of dose response of SyB D-0701 to preventing effects for nausea and emesis associated with radiotherapy (fractionated/localized irradiation)

研究设计

研究类型
Interventional
干预模型
Parallel
盲法
Double

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

SyB D-0701: high dose group

Experimental

干预措施: SyB D-0701 (Drug)

SyB D-0701: low dose group

Experimental

干预措施: SyB D-0701 (Drug)

SyB D-0701: low dose group

Experimental

干预措施: Placebo (Drug)

placebo group

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Complete Control (no Signs of Emesis or Moderate to Severe Nausea and no Use of Rescue Medication) Rate From the Start of Radiotherapy Until 24 Hours After the Third Irradiation

时间窗: 72 hours

The complete control rate was defined as the percentage of subjects who had no emesis and no moderate or more severe nausea and who used no rescue drugs during the period from the time of the first irradiation to 24 hours after the third irradiation.

次要结局

  • Complete Response (no Signs of Emesis and no Use of Rescue Medication) Rate From the Start of Radiotherapy Until 24 Hours After the Third Irradiation(72 hours)
  • Time to First Emesis(24-72 hours)
  • Complete Response Rate Within 24 Hours After Each Irradiation From Sessions 1 to 3(24-72 hours)
  • Severe (Grade 3 or More) Adverse Events(Up to 192 hours)
  • Adverse Events(Up to 192 hours)
  • Skin Manifestations at Study Drug Application Site(Up to 192 hours)
  • Time to First Nausea(24-72 hours)
  • Complete Control Rate Within 24 Hours After Each Irradiation From Sessions 1 to 3(24-72 hours)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验